Fibrinolysis is a physiological process in which blood clots are broken down and dissolved. This process is essential for maintaining proper blood flow and preventing the formation of excessive or abnormal blood clots. Fibrinolysis is primarily carried out by enzymes called plasmin, which degrade fibrin, a protein that forms the structural framework of blood clots. Research in the field of fibrinolysis aims to understand the mechanisms that regulate this process, identify factors that can enhance or inhibit fibrinolysis, and develop new treatments for disorders characterized by abnormal blood clot formation. This research is crucial for improving the management of conditions such as myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism, which are all associated with disturbances in the fibrinolytic system. Additionally, understanding fibrinolysis can provide insights into the pathophysiology of other diseases, such as cancer and inflammation, where abnormal blood clot formation may play a role.